Business
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies FLORHAM PARK, N.J., July 14, 2022 (GLOBE
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies\nFLORHAM PARK, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced an upcoming poster presentation at the 41st annual meeting of the American Society of Virology meeting. The study demonstrated that the investigational universal flu vaccine was effective against multiple strains of the influenza virus. In this preclinical study, PDS0202, in which Infectimune™ is formulated with Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens developed by the laboratory of renowned influenza expert, Dr. Ted Ross, was evaluated for its potential ability to provide effective and broad neutralization of multiple influenza strains as well as to provide protection against infection. Highlights include: Animals vaccinated with PDS0202 demonstrated significantly higher antibody titers against H1 and H3 influenza strains compared to animals vaccinated without Infectimune™.All animals vaccinated with PDS0202 survived a lethal challenge with the H1N1 pandemic strain of influenza, compared to a ~40% survival rate in animals vaccinated with COBRA antigens only and a 0% survival rate in untreated animals.Infectimune™ allowed for significant dose-sparing with effective protection demonstrated using 25-fold lower doses of the COBRA antigens in animals.No detectable virus was found in lungs from animals treated with PDS0202, compared to the presence of high virus titers in lungs evaluated both from animals treated only with COBRA antigens and also in the untreated animals.The COBRA antigens elicit broadly reactive antibody responses to influenza, and Infectimune™ can promote antigen cross-presentation leading to higher immunogenicity with enhanced levels of antibody and T cell responses resulting in reduced doses of vaccine to protect against viral challenge in animals. “We are pleased to share the potential of the novel Infectimune™ and COBRA-based investigational vaccine with the virology community,” said Lauren V. Wood, MD, Chie...